Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction chemotherapy + Finotonlimab with or without high/low-dose radiotherapy in resectable locally advanced head and neck squamous cell carcinoma
ChiCTR2500109989Phase 2Not yet recruiting
- Sponsor
- Jiangxi Cancer Hospital
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of finotonlimab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Jiangxi Cancer Hospital. Primary endpoint: Major pathological response rate. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
finotonlimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2500109989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109989.